Vertex Pharmaceuticals Incorporated

Otsuka’s release of supplemental Phase III data on June 6 for sibeprenlimab was the second major data readout in immunoglobulin A nephropathy (IgAN) of the week, following Vera’s Phase III data on Jun

The US Food and Drug Administration has successfully helped pull stalled cell and gene therapy programs off the cutting room floor in recent years and wants sponsors who might benefit from the agency’

Vera Therapeutics reported 36-week results on June 2 from the ORIGIN Phase III clinical trial of its B-cell modulator atacicept in the treatment of immunoglobulin A nephropathy (IgAN) in adults, showi

Who: Eli Lilly/SiteOne Therapeutics What: Lilly has agreed to acquire privately held SiteOne and its Phase II-ready Nav1.8 inhibitor for pain for up to $1bn. Why: Pain is an area of therapeutic f